Cost-effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain.

Publisher: Becaris Publishing Country of Publication: England NLM ID: 101577308 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2042-6313 (Electronic) Linking ISSN: 20426305 NLM ISO Abbreviation: J Comp Eff Res Subsets: MEDLINE

Publication: 2023- : Royston, UK : Becaris Publishing
Original Publication: London : Future Medicine

Osteoporosis, Postmenopausal*/drug therapy ; Bone Density Conservation Agents*/therapeutic use ; Fractures, Bone*; Humans ; Female ; Alendronate/therapeutic use ; Risedronic Acid/therapeutic use ; Cost-Benefit Analysis ; Cohort Studies ; Spain/epidemiology ; Etidronic Acid/therapeutic use ; Quality-Adjusted Life Years

Aim: To estimate the cost-effectiveness of treating postmenopausal osteoporosis (PMO) with weekly gastro-resistant risedronate 35 mg gastro-resistant tablets (RIS-GR), compared with weekly alendronate 70 mg tablets (ALN) in Spain. Methods: A probabilistic analysis (second-order Monte Carlo simulation) was performed with a time horizon of 5 years, from the perspective of the Spanish National Health System. The bone fracture probabilities were obtained from a cohort study of 3614 women from USA with PMO treated with RIS-GR (1807) or ALN (1807) (Thomasius, 2022). The pharmacological cost and the cost of fractures were obtained from Spanish sources (€ 2022). The utilities of patients with and without fracture (quality-adjusted life years [QALYs]) were obtained from the medical literature. Results: Compared with ALN, treatment with RIS-GR can avoid 79 fractures (between 75 and 82) every 1000 patients treated, and 0.0119 QALYs would be gained (between 0.0098 and 0.0140) per patient. Additionally, GR-RIS would generate a cost saving per patient of €1994 (€1437-2904) with a probability of 99.7%. The scenario analyses confirmed the stability of the base case results. Conclusion: According to this study, RIS-GR would be the dominant treatment (lower costs with QALY gain) compared with ALN.

Bone Rep. 2015 Oct 30;4:5-10. (PMID: 28326336)
Climacteric. 2015;18(4):608-16. (PMID: 25495333)
Osteoporos Int. 2019 Mar;30(3):649-658. (PMID: 30701342)
Expert Rev Pharmacoecon Outcomes Res. 2016 Jun;16(3):359-70. (PMID: 27015247)
Expert Rev Pharmacoecon Outcomes Res. 2021 Oct;21(5):1127-1133. (PMID: 34047214)
Expert Rev Pharmacoecon Outcomes Res. 2021 Apr;21(2):315-320. (PMID: 32597317)
Rev Esp Cir Ortop Traumatol (Engl Ed). 2019 Jan - Feb;63(1):56-68. (PMID: 29793855)
Ther Adv Musculoskelet Dis. 2022 Mar 20;14:1759720X221083541. (PMID: 35342458)
Arch Osteoporos. 2021 Jun 2;16(1):82. (PMID: 34080059)
Clinicoecon Outcomes Res. 2015 Feb 09;7:105-17. (PMID: 25709480)
BMC Musculoskelet Disord. 2007 Sep 26;8:97. (PMID: 17897451)
Clin Pharmacol Ther. 2022 Jan;111(1):135-144. (PMID: 34726771)
Osteoporos Int. 2019 Jan;30(1):3-44. (PMID: 30324412)
PLoS One. 2021 Jul 9;16(7):e0253450. (PMID: 34242228)
Ther Clin Risk Manag. 2013;9:395-402. (PMID: 24204155)
Osteoporos Int. 2013 Jan;24(1):301-10. (PMID: 23079690)
Osteoporos Int. 2022 Jan;33(1):217-228. (PMID: 34490504)
J Intern Med. 2015 Jun;277(6):650-61. (PMID: 25832448)

Keywords: alendronate; cost–effectiveness; postmenipausal osteoporosis; risedronate gastro-resistant

X1J18R4W8P (Alendronate)
KM2Z91756Z (Risedronic Acid)
0 (Bone Density Conservation Agents)
M2F465ROXU (Etidronic Acid)

Date Created: 20230915 Date Completed: 20231101 Latest Revision: 20240423

20240423

PMC10690429

10.57264/cer-2023-0115

37712635